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Abstract Assess the feasibility of whole body magnetic
resonance angiography (WB-MRA) for monitoring global
atheroma burden in a population with peripheral arterial
disease (PAD). 50 consecutive patients with symptomatic
PAD referred for clinically indicated MRA were recruited.
Whole body MRA (WB-MRA) was performed at baseline,
6 months and 3 years. The vasculature was split into 31
anatomical arterial segments. Each segment was scored
according to degree of luminal narrowing: 0 = normal,
1 =\50 %, 2 = 50–70 %, 3 = 71–99 %, 4 = vessel
occlusion. The score from all assessable segments was
summed, and then normalised to the number of assessable
vessels. This normalised score was divided by four (the
maximum vessel score) and multiplied by 100 to give a
final standardised atheroma score (SAS) with a score of
0–100. Progression was assessed with repeat measure
ANOVA. 36 patients were scanned at 0 and 6 months, with
26 patients scanned at the 3 years follow up. Only those
who completed all three visits were included in the final
analysis. Baseline atherosclerotic burden was high with a
mean SAS of 15.7 ± 10.3. No significant progression was
present at 6 months (mean SAS 16.4 ± 10.5, p = 0.67),
however there was significant disease progression at
3 years (mean SAS 17.7 ± 11.5, p = 0.01). Those with
atheroma progression at follow-up were less likely to be on
statin therapy (79 vs 100 %, p = 0.04), and had signifi-
cantly higher baseline SAS (17.6 ± 11.2 vs 10.7 ± 5.1,
p = 0.043). Follow up of atheroma burden is possible with
WB-MRA, which can successfully quantify and monitor
atherosclerosis progression at 3 years follow-up.
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Introduction
Atherosclerosis is the pathological process underpinning
the leading causes of morbidity and mortality in the
western world. Despite the fact that it typically presents
with symptoms localising to a single site, atherosclerosis is
a systemic process, with those with disease presenting in
one site at markedly increased risk for developing symp-
tomatic disease at another site [1]. Peripheral arterial dis-
ease (PAD) is particularly prone to this with previous
reports showing a high prevalence of silent myocardial
infarctions, extra-site disease, and risk of future cardio-
vascular events [2–4].
Whole body magnetic resonance angiography (WB-
MRA) has been proven to be useful for assessing the
atheroma burden throughout the body in both healthy
volunteers and patients with cardiovascular disease [5–7].
This has been shown to correlate well with the presence of
obstructive coronary arterial disease, and as a predictor of
future major adverse cardiovascular events [8–10]. How-
ever the ability to assess and quantify atheroma progression
with WB-MRA has not been previously investigated.
Therefore we set out to determine the feasibility of using
WB-MRA to quantify and monitor atheroma progression in
a population with PAD.
Materials and methods
Institutional review board and research and development
committee approval was granted for this study. All enrolled
participants gave written informed consent. 50 consecutive
patients referred for MRA of their lower limbs with PAD
and symptomatic claudication were recruited. Disease
severity was classified using the Fontaine scoring system.
All patients underwent WB-MRA at baseline, with repeat
WB-MRA scans being performed at 6 months, and 3 years
after baseline. The baseline data of the full cohort have
been described in detail previously, while the current
article focuses on the longitudinal follow-up and assess-
ment of the cohort [11].
WB-MRA
At baseline and 6 months, all scanned patients underwent
contrast-enhanced WB-MRA using a 1.5T MRI unit (Sie-
mens Magnetom Avanto, Erlangen, Germany). Fifty con-
secutive patients were recruited to the study. Four patients
were excluded due to inability to complete the MRI
examination due to claustrophobia, leaving 46 participants
who received the baseline scan. A total of 36 participants
completed the 6 months follow-up study, and 26 returned
for the 3 years follow-up scan. Drop outs were due to: two
deaths; eight who had developed subsequent health com-
plications and felt unable to continue; and ten who were
uncontactable. At 3 years follow-up, 26 participants were
scanned: n = 8 were scanned at 1.5T and n = 18 were
scanned on a 3T MRI unit (Siemens Magnetom Trio,
Erlangen, Germany).
Patients were imaged head first and supine in the magnet
bore, with surface coils used to cover the entire body as
follows: one head matrix; one neck matrix; one spine
matrix; two body matrix; and one peripheral angiography.
WB-MRA was performed using four separate stations for
image acquisition, as below:
Station 1—head, neck and thoracic vessels
Station 2—abdominopelvic vessels
Station 3—upper leg vessels
Station 4—lower leg vessels
Full details of the technique are described in detail else-
where [11], but in brief, the examination consisted of pre-
contrast (‘mask’) and post-contrast MR imaging at all
anatomical stations using a fast spoiled gradient echo
(FLASH—Siemens, Germany) sequence. After the pre-
contrast images for station 1 and 4 had been acquired,
20 ml of 0.5 M intravenous gadolinium based contrast
agent (gadoterate meglumine, Guerbet, FR) followed by a
20 ml volume of normal saline was administered at 1 ml/s
using an injector pump via a 20G venflon in the antecubital
fossa using a dual injection method [12]. Following this, a
fluoroscopic-guided post-contrast FLASH sequence was
implemented at station 1 when the contrast agent reached
the aortic arch. Immediately thereafter, the same FLASH
acquisition was completed at station 4 on three consecutive
occasions (to optimise the peak contrast enhancement at
the lower limb vessels).
After a 10 min delay, the pre-contrast mask for stations
2 and 3 were acquired following which the second injection
of contrast agent was delivered and flouroscopic guided
triggering was used at the proximal abdominal aorta to
define the start of the FLASH acquisition for station 2.
Finally, FLASH data for station 3 were acquired immedi-
ately after completion of the station 2 sequence.
The resulting images were analysed by dividing the
arterial tree into 31 distinct anatomical segments. Each
segment was scored according to the maximal stenosis
present at any point within it, using a 5 point scoring
system:
• 0: Normal vessel
• 1:\50 % stenosis
• 2: 50–70 % stenosis
• 3:[70 % stenosis
• 4: Completely occluded vessel
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Arterial segments which were not visualised with sufficient
clarity for grading of the degree of stenosis were not
analysed. To account for this, the final score was divided
by the number of segments which had been successfully
analysed (n), and then calculated as a percentage of the
maximum possible score (see equation below) to produce a
‘standardised atheroma score’ (SAS) [13].







The 31 vessel segments were also subdivided into 5
anatomical territories: (1) the head and neck arteries; (2)
the aorta; (3) the abdominal arteries; (4) the ilio-femoral
arteries; and (5) popliteal and infrageniculate arteries
(Fig. 1). Regional SASs were calculated for each anatom-
ical territory.
WB-MRA analysis was performed using a diagnostic
PACS radiological workstation (Carestream PACS Client
Suite Version 10.1 sp1, Rochester, NY, USA) using the
raw data in multiplanar reformat (MPR) analysis. Multi-
planar visualisation was used in order to best visually
estimate the degree of area stenosis. All images were
analysed by a single radiologist with over 3 years experi-
ence in vascular radiology blinded to the patients’ clinical
details. In order to determine repeatability of the scoring 26
scans from the final study visit were scored twice by this
observer with a greater than 6 months interval between
readings, and by two additional observers (one with over
3 years, and the other with over 20 years experience in
vascular radiology). 2-way mixed, absolute agreement,
average measure intraclass correlation co-efficient (ICC)
for the whole body SAS was 0.94 (95 % CI 0.82–0.98) for
intra-observer repeatability, and 0.89 (95 % CI 0.63–0.96)
for inter-observer variability between the 3 observers
(ICC[ 0.75 = excellent, 0.4–0.75 = good, \0.4 = poor,
\0.2 = slight).
Ankle Brachial Pressure Index (ABPI) and carotid
intima media thickness (CIMT)
These were performed as previously described [11].
Briefly, the CIMT was measured 1 cm proximal to the
carotid bulb at a point where 1 cm of continuous intima
media could be visualised. Both common carotids were
measured twice and an average obtained.
ABPI was calculated using the highest of the two upper
limb brachial blood pressures, and the higher of the two
lower limb blood pressures.
Statistical analysis
Categorical variables are presented as frequencies or per-
centages; normally distributed continuous variables are
presented as means ± SD; and skewed variables are
presented as median with interquartile range (IQR; 25–75th
percentile). Normality of continuous variables was tested
with the Shapiro–Wilk test. An independent sample t test
was used to compare demographics between those with and
without atheroma progression. Repeated measure ANOVA
Fig. 1 Examples of atheroma progression (a, b) and regression (c, d).
MRA of the right iliac artery at baseline (a) showing a grade 2
(50–70 %) stenosis just distal to the internal iliac artery origin which
has progressed to a grade 3 (70–99 %) stenosis at 3 years follow-up
(b). MRA of the iliac artery in patient with interval angioplasty
showing baseline grade 3 stenosis (c) which resolves on follow-up
with only minor remaining luminal irregularity (grade 1) (d)
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was used to analyse SAS progression between the baseline
and 3 years follow up visit, with a post hoc analysis with
bonferonni correction for differences between the three
visits. A p value of\0.05 was considered significant. All
statistical analyses were performed with IBM SPSS
Statistics for Windows, version 21.0 (IBM Corp., NY,
USA).
Results
Fifty consecutive patients were recruited to the study. Four
patients were excluded due to inability to complete the
MRI examination due to claustrophobia, leaving 46 par-
ticipants who received the baseline scan. A total of 36
participants completed the 6 months follow-up study, and
26 returned for the 3 years follow-up scan. Drop outs were
due to: two deaths; eight who had developed subsequent
health complications and felt unable to continue; ten who
were uncontactable. Of the final 26, 73 % (n = 19) were
male, with a mean age of 64.5 ± 9.5 years. A summary of
demographic data is provided in Table 1. In terms of
symptomatic PAD severity, 2 patients were Fontaine 1, 2
were Fontaine IIa, 35 were Fontaine IIb, 5 were Fontaine
III and 2 were Fontaine IV. There was no significant dif-
ferences in the demographics or baseline atheroma burden
between those who completed all three visits and those
who dropped out (p[ 0.1 for all variables).
There were 2418 segments for analysis. Of the 2418
possible segments, 2387 (98.7 %) were considered to be of
sufficient quality for analysis. At baseline SAS was
15.7 ± 10.3, with a mean SAS of 16.4 ± 10.5 at 6 months,
and a mean SAS of 17.7 ± 11.5 at 3 years. No significant
progression was present at 6 months with a change in SAS
of 0.63 ± 0.51 (p = 0.67). This lack of significant pro-
gression persisted even when all 36 who underwent the first
two scans were included in the analysis (mean progression
0.96 ± 1.08, p = 0.38). There was significant disease
progression at 3 years with a mean progression in SAS of
1.92 ± 1.24 (p = 0.01). Over the 3 years period, this gave
an annual progression rate in the atheroma burden of 4.1 %
per year. Significant progression was also present between
the 6 months SAS and the 3 years follow-up (mean pro-
gression 1.29 ± 0.84, p = 0.016)—see Fig. 2.
At 3 years eighteen participants showed progression in
their atheroma score, while two were stable, and six
showed an improvement (see Fig. 3). Out of the six whose
atheroma score reduced, three had undergone one or more
percutaneous interventions (one with femoral angioplasty,
one with bilateral iliac angioplasties, one with bilateral
femoral angioplasties with unilateral stent insertion). One
patient had a single intervention between visit 1 and 2, one
had a single intervention between visit 2 and 3, and one had
2 separate visits for interventional procedures with one
between each visit. The remaining three had no interven-
tion to explain their improvement. In comparison two
participants demonstrated atheroma progression despite
interval percutaneous intervention (one with two
Table 1 Demographics and clinical characteristics of the study
population
Study population (n = 26)
Male (%) 19 (73 %)
Age (years) 64.5 ± 9.6
BMI (kg/m2) 28.4 (20.7–41.2)
Systolic BP (mmHg) 145 ± 11
Diastolic BP (mmHg) 82 (43–102)
Type 2 diabetes 5 (19 %)
Hypertension 18 (69 %)
Smoking status
Current smoker 5 (19 %)
Ex-smoker 19 (73 %)
Non-smoker 2 (8 %)
Smoking pack years 38 ± 34
Medications
Anti-hypertensive 19 (73 %)
Anti-platelet 22 (85 %)
Statin 22 (85 %)
Baseline SAS 15.7 ± 10.3
CIMT 0.94 ± 0.18
ABPI 0.82 (0.51–2.05)
Values expressed as mean ± SD, median (range) or N (%)
BMI body mass index, BP blood pressure, SAS standardised atheroma
score, CIMT carotid intima media thickness, ABPI ankle-brachial
pressure index
Fig. 2 Comparison of atheroma score at baseline, 6 months and
3 years. SAS standardized atheroma score. T-bars represent 95 %
confidence intervals
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angioplasties and a stent inserted between the first two
scans, the other with a common iliac stent inserted between
the first and second scan). When the participants who were
scanned at 1.5T on the final visit were compared with those
scanned at 3T on the third visit there was no difference in
the final visit atheroma burden (1.5T: 16.6 ± 9.2, 3T
18.1 ± 12.6, p = 0.75) or rate of progression (1.5T:
1.7 ± 2.7, 3T 2.2 ± 3.2, p = 0.71).
Whilst the whole body SAS demonstrated significant
progression over the 3 years, when this was split into five
distinct anatomical regions, no single region demonstrated
significant progression on its own over the 3 years [(1)
head and neck (mean difference 1.4 ± 4.7, p = 0.4); (2)
aorta (mean difference 1.9 ± 4.3, p = 0.09); (3) the
abdominal arteries (mean difference 0.96 ± 8.9, p = 01);
(4) ilio-femoral arteries (mean difference 2.5 ± 5.1,
p = 0.16); and (5) popliteal and infrageniculate arteries
(mean difference 3.0 ± 3.0, p = 0.15), (see Table 2)].
Out of the baseline characteristics, statin therapy was
significantly more common in the group showing no pro-
gression than those with progression (100 vs 79 %,
p = 0.04). In addition, baseline SAS was significantly
higher in those who progressed compared with those with
stable disease/atheroma regression (17.6 ± 11.2 vs
10.7 ± 5.1, p = 0.043) (see Table 3).
Discussion
In this feasibility study we have demonstrated the possi-
bility of using WB-MRA to monitor and quantify
atherosclerosis progression in a population with PAD. To
the best of the authors knowledge, this is the first time that
sequential WB-MRA has been used to quantify the pro-
gression rates of stenotic arterial disease. This adds to the
current literature which shows that WB-MRA can detect
significant arterial pathology outwith the lower limbs, more
accurately quantifies stenotic disease in the lower limbs
Fig. 3 Bland Altman plot comparing baseline SAS (x-axis) with SAS
change at 3 years (y-axis). The mid, upper and lower line represents
the mean, and upper and lower 1.96*SD, of the change in SAS
between baseline and 3 years follow up respectively
Table 2 Change in whole body
and regional SAS between
baseline and 3 years follow-up
Baseline 3 years Mean difference p
WB-SAS 15.7 ± 10.3 17.7 ± 11.5 2.0 ± 3.1 0.014
Head/neck-SAS 9.0 ± 11.2 10.4 ± 11.7 1.4 ± 4.7 0.4
Aorta-SAS 13.5 ± 8.5 15.4 ± 6.9 1.9 ± 4.3 0.09
Abdomen-SAS 9.2 ± 12.5 10.2 ± 11.7 0.96 ± 8.9 1
Ilio-femoral-SAS 32.2 ± 17.5 34.3 ± 19.7 2.5 ± 5.1 0.16
Run off-SAS 15.8 ± 19.6 18.8 ± 22.2 3.0 ± 3.0 0.15
Values expressed as mean (95 % CI)
SAS standardised atheroma score
Table 3 Comparison of baseline characteristics between those with
and without atheroma progression at 3 years follow-up
Progression Stable/regression p
N 18 (69 %) 8 (31 %)
Male (%) 15(79 %) 4(57 %) 0.29
Age (years) 66.3 ± 10.3 59.6 ± 4.7 0.11
BMI (kg/m2) 28.7 (20.7–36.5) 28 (24.9–41.2) 0.41
Systolic BP (mmHg) 144.8 ± 11.4 148.6 ± 11.9 0.47
Diastolic BP (mmHg) 81 (43–102) 84 (68–95) 0.57
Pulse pressure 64.5 ± 14.3 65.9 ± 15.5 0.83
Hypertension 13 (68 %) 5 (71 %) 0.89
Type 2 diabetes 3(16 %) 2(29 %) 0.48
Current smoker 4 (21 %) 1 (14 %) 0.71
Ex-smoker 14 (74 %) 5 (71 %) 0.91
Non-smoker 1 (5 %) 1 (14 %) 0.46
Smoking pack years 30.4 ± 21.6 55.4 ± 50.1 0.1
Anti-hypertensive 13 (68 %) 6 (86 %) 0.35
Anti-platelet 17 (89 %) 5 (71 %) 0.39
Statin 15 (79 %) 7 (100 %) 0.04
Baseline SAS 17.6 ± 11.2 10.7 ± 5.1 0.043
CIMT 0.94 ± 0.19 0.93 ± 0.18 0.92
ABPI 0.8 (0.51–2.05) 0.84 (0.72–1.37) 0.85
The bold values indicate statistically significant (p\ 0.05)
Values expressed as mean ± SD, median (range) or N (%)
BMI body mass index, BP blood pressure, SAS standardised atheroma
score, CIMT carotid intima media thickness, ABPI ankle-brachial
pressure index
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than ABPI, and can effect management changes in this
population [3, 14, 15]. Additionally, the extra cost of
extending standard lower limb MRA to include whole body
imaging in combination with a cardiac MRI has been
shown to be cost-effective due to a reduction in the
requirement for down stream extra tests [16].
The ability to quantify and monitor atherosclerosis is
desirable for several reasons. Previous studies have shown
atheroma burden to correlate better with future cardiovas-
cular events than traditional risk factors, and therefore
holds potential as a useful prognostic marker. Furthermore,
the ability to identify early changes in a small number of
people holds potential to be a useful in early identification
of drug efficacy. The benefits of identifying such markers is
well evidenced in the rapid uptake in the use of cardiac
MRI in the quantification of left ventricular mass and
volumes in drug studies, where the high reproducibility
results in a reduction in study size number of 55–93 %,
with the observed changes in ventricular measures corre-
lating well with outcomes [17, 18]. CIMT and carotid-
femoral pulse wave velocity (cfPWV) have also been used
as surrogate markers for assessment of atherosclerosis
progression. Of these, CIMT is the best studied, with
reported progression rates of 0.0147 mm/year [19]. How-
ever, due to the resolution of ultrasound being in the range
of 0.1–0.3 mm, and a 5–10 % measurement error, indi-
vidual progression monitoring is not possible and the
number required for observational studies is still relatively
high [20]. Progression rates of cfPWV have previously
been reported as 8.1–14.7 mm/s/year observed in a popu-
lation of 483 subjects over a 6 years period, thus also
requiring large numbers and long time periods to demon-
strate change [21]. The strength of the WB-MRA technique
appears to arise in its systemic assessment. When the
arterial system was subdivided into five clinically separate
areas no significant change over the 3 years was apparent
in any of them. It was only when all 31 arterial segments
were combined that progression could be observed. This
may in part be due to the small number of subjects in our
current study meaning significant progression could not be
observed in individual arteries or regions. While larger
study numbers may allow regional assessment of progres-
sion, this detracts from the two strengths of the whole body
MRA technique, the first being its systemic assessment of a
systemic disease process, and the second being its potential
to reduce study sizes by detecting changes in a smaller
number of individuals. While whole body CTA has pre-
viously been used to derive a similar whole body atheroma
score, and has the benefit of providing coronary artery
assessment at the same time, it is associated with a high
radiation dose and a relatively high contrast dose [22].
The small number of patients who completed the pro-
tocol limits the generalisability of the results. However the
current study was to determine feasibility rather than to
definitively quantify atheroma progression rates. Despite
the small number of participants, significant disease pro-
gression could still be observed. The validity of our find-
ings is strengthened by the observation that those with
atheroma progression were significantly less likely to be
prescribed statins and to have higher SAS on their baseline
WB-MRA. This is entirely consistent with studies in
coronary artery calcium (CAC) scoring—a measure of
calcified atheroma burden within the coronaries—showing
higher CAC progression in those with higher baseline CAC
[23], and lower progression rates in those on statins [24].
While a high drop out rate is problematic and raises con-
cerns about patient acceptance of the technique, a previous
study has shown higher acceptance of WB-MRA over
digital subtraction angiography and thus the high attrition
rate may be due to the high morbidity of the patient pop-
ulation studied, indeed half of our observed attrition rate
was due to declining health [25].
Larger studies will be required to verify the repro-
ducibility of these results, and also to explore the appli-
cability in other cardiovascular disease cohorts, especially
as PAD is known to have a higher atheroma burden, and
therefore is likely to have a higher and therefore more
easily measurable progression in atheroma burden. Addi-
tionally, the clinical significance of the WB-MRA pro-
gression data observed in this study needs to be established.
The current study has several limitations. The popu-
lation is heterogenous as all clinical referrals for claudi-
cation assessment were recruited rather than a specifically
defined disease severity. Despite this the majority of the
participants were Fontaine IIb, and this heterogeneity also
better reflects the spectrum of disease seen in routine
clinical practice. In addition our analysis comparing the
progression and regression groups could be confounded
by the inclusion of participants who underwent interven-
tional procedures, as this group could be considered
clinical progressors due to their need for intervention,
while those with no intervention and regression would be
considered as true (or at least medically induced)
regressors. However our results are commensurate with
prior work in CAC [23, 24], and the study was neither
designed nor of sufficient size to undertake this type of
subgroup analysis. Further work is thus required to
extricate the true effects of medical intervention. The
magnetic field strength used for baseline and 3 years
follow-up examinations was different in some cases for
operational reasons. All participants were scanned using
the 1.5T machine at baseline and 6 months, and 70 % of
participants were scanned at 3T at the final 3 years fol-
low-up. While this could potentially account for some of
the temporal changes observed, previous studies have
reported no significant differences in stenosis assessment
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between the two field strengths [26]. In addition there
were no differences in progression rates between those
scanned at 1.5T at all visits and those scanned at 3T at
follow-up.
Whole body magnetic resonance angiography is a
lumenographic technique, thus early wall thickening and
extra-luminal plaque formation will be missed potentially
underestimating disease. Whilst techniques such as iso-
tropic black blood imaging may hold the potential for
analysis of early wall thickening and stenosis assessment,
this technique has yet to be used and validated in whole
body vascular assessment, unlike the current angiographic
technique. Furthermore other scores such as the Dukes
score and modified Dukes score for invasive coronary
angiography and CT coronary angiography have well
demonstrated the strength of lumenographic techniques
for quantification of disease burden and future prognosis
[27].
Conclusion
Whole body contrast-enhanced magnetic resonance
angiography allows monitoring and quantitative assess-
ment of global plaque burden over time. In patients with
PAD, significant increases in atheroma burden can be
observed over a 3 years period.
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